Hypertension

The Hypertension pipeline: 47 tracked drugs, 3 approved for this indication.

3 approved / phase 417 Phase 39 Phase 21 Phase 1/29 Phase 18 preclinical / unstaged

Compare the share prices of listed companies in Hypertension →

Total attributable cost

$347.4B

$2,759/patient

Drug spend

$34.5B

$274/patient

How this is calculated ↗

All severities (2017 ACC/AHA threshold) · US

The Hypertension pipeline

Key trial results for every approved and late-stage drug: Hypertension results by drug.

← all assets